Related references
Note: Only part of the references are listed.Effects of weight changes in the autonomic nervous system: A systematic review and meta-analysis
Joao Costa et al.
CLINICAL NUTRITION (2019)
Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril
Agustin J. Ramirez et al.
JOURNAL OF HYPERTENSION (2019)
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
Keith C. Ferdinand et al.
CIRCULATION (2019)
Obesity and its cardiovascular effects
Christian Ortega-Loubon et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Microvascular complications in diabetes: A growing concern for cardiologists
Angelo Avogaro et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Tuba M. Ansary et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation
Stefano Masi et al.
VASCULAR PHARMACOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study
Kazuomi Kario et al.
CIRCULATION (2019)
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Di Zhao et al.
JOURNAL OF HUMAN HYPERTENSION (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity
Klara Komici et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2019)
Type 2 Diabetes and Thiazide Diuretics
Andre J. Scheen
CURRENT DIABETES REPORTS (2018)
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Anne Pernille Ofstad et al.
HEART FAILURE REVIEWS (2018)
Caloric Restriction and Its Effect on Blood Pressure, Heart Rate Variability and Arterial Stiffness and Dilatation: A Review of the Evidence
Rachel Nicoll et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Motoaki Sano
JOURNAL OF CARDIOLOGY (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
Lakshini Y. Herat et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2018)
SGLT2 Inhibitors and Mechanisms of Hypertension
Alexandros Briasoulis et al.
CURRENT CARDIOLOGY REPORTS (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
Atsutaka Yasui et al.
DIABETES THERAPY (2018)
Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
P. C. Lee et al.
OBESITY REVIEWS (2018)
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
Yoshiaki Kubota et al.
DIABETES THERAPY (2018)
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Ningning Wan et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure
Tsuneo Takenaka et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report
Shunsuke Kiuchi et al.
DRUG DISCOVERIES AND THERAPEUTICS (2018)
Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension
Tomohiko Kimura et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis
Xiaoling Cai et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
Hiroyuki Tanaka et al.
ADVANCES IN THERAPY (2017)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Marc van Bilsen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Jasdeep Kaur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Vance B. Matthews et al.
JOURNAL OF HYPERTENSION (2017)
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
Jens Jordan et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Mohsen Mazidi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Contribution of Autonomic Reflexes to the Hyperadrenergic State in Heart Failure
Edgar Toschi-Dias et al.
FRONTIERS IN NEUROSCIENCE (2017)
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
Shin Kawasoe et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Factors Responsible for Obesity-Related Hypertension
Kyungjoon Lim et al.
CURRENT HYPERTENSION REPORTS (2017)
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ele Ferrannini
CELL METABOLISM (2017)
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
A. J. Scheen et al.
DIABETES & METABOLISM (2017)
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials
Atsunori Kashiwagi et al.
DIABETOLOGY INTERNATIONAL (2017)
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Christian Ott et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Martin Lorenz et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension
Raymond R. Townsend et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
Andre J. Scheen
DIABETES & METABOLISM (2016)
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
A. J. Scheen
DIABETES & METABOLISM (2016)
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
H. J. L. Heerspink et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
Giuseppe Mancia et al.
HYPERTENSION (2016)
Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes
Kouichi Tamura et al.
HYPERTENSION RESEARCH (2016)
EMPA-REG - the diuretic hypothesis
John McMurray
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
Harindra Rajasekeran et al.
KIDNEY INTERNATIONAL (2016)
Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Rosemary H. Elliott et al.
NEPHROLOGY (2016)
Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis
E. Zomer et al.
OBESITY REVIEWS (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
Michael A. Weber et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure
James W. Reed
VASCULAR HEALTH AND RISK MANAGEMENT (2016)
The Sympathetic Nervous System Alterations in Human Hypertension
Guido Grassi et al.
CIRCULATION RESEARCH (2015)
Cardiac Innervation and Sudden Cardiac Death
Keiichi Fukuda et al.
CIRCULATION RESEARCH (2015)
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2015)
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C. David Sjostrom et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
C. D. Sjostrom et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Konstantinos P. Imprialos et al.
JOURNAL OF HYPERTENSION (2015)
SGLT2 inhibitors: their potential reduction in blood pressure
George Maliha et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Metabolic syndrome: a sympathetic disease?
Markus Schlaich et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Sympathetic Activity and Markers of Cardiovascular Risk in Nondiabetic Severely Obese Patients: The Effect of the Initial 10% Weight Loss
Elisabeth A. Lambert et al.
AMERICAN JOURNAL OF HYPERTENSION (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Matthew R. Weir et al.
JOURNAL OF CLINICAL HYPERTENSION (2014)
Sudden cardiac death and diabetes mellitus
I. Vasiliadis et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
Raymond V. Oliva et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus
G. S. Hillis et al.
DIABETOLOGIA (2012)
The human sympathetic nervous system: its relevance in hypertension and heart failure
Gianfranco Parati et al.
EUROPEAN HEART JOURNAL (2012)
Diabetes and hypertension: the bad companions
Ele Ferrannini et al.
LANCET (2012)
Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy
Geoffrey B. Arden et al.
CURRENT DIABETES REVIEWS (2011)
Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity: Role of Sympathetic Nerve Activity and Insulin Resistance
Kazuko Masuo et al.
CURRENT DIABETES REVIEWS (2010)
Heart Rate as a Risk Factor for Cardiovascular Disease
Christine Perret-Guillaume et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2009)
Sympathetic dysfunction in type 1 diabetes - Association with impaired myocardial blood flow reserve and diastolic dysfunction
R Pop-Busui et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Sympathetic and baroreflex function in hypertension: Implications for current and new drugs
G Grassi
CURRENT PHARMACEUTICAL DESIGN (2004)
Autonomic nervous function, arterial stiffness and blood pressure in patients with Type I diabetes mellitus and normal urinary albumin excretion
FJ van Ittersum et al.
JOURNAL OF HUMAN HYPERTENSION (2004)
Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension
RJ Huggett et al.
CIRCULATION (2003)
Influence of weight reduction on blood pressure - A meta-analysis of randomized controlled trials
JE Neter et al.
HYPERTENSION (2003)
Antihypertensive drugs and sympathetic nervous system
F Rabbia et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2001)
Share Paper
